Search Results - joseph+steiner

3 Results

Sort By:

Novel inhibitors of protein kinase signaling that are neuroprotective and have potential applicability for the treatment of glaucoma, optic nerve disease, and other forms of neurodegeneration - #2

Glaucoma is a major cause of visual loss and blindness in elderly Americans and throughout the world. One approach to treatment of glaucoma, and other optic nerve diseases as well as other neurodegenerations, is to develop neuroprotective agents that promote the survival of neurons. Through a high content screen of libraries of small molecule compounds,...

Published: 7/4/2024 | Inventor(s): Laszlo Hackler, Dana Ferraris, Cynthia Berlinicke, James Inglese, Tomas Vojkovsky, Joseph Steiner, Barbara Slusher, Zhiyong Yang, Donald Zack

Keywords(s): Antagonists/Inhibitors, CNS and Neurological Disorders, Disease Indication, Eye Disorders, Multiple CNS Indications, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Ophthalmology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities

Role of Limonoid Compounds As Neuroprotective Agents

Invention novelty: A series of compounds from the limonoid family that can be used in protecting neurons from different types of toxicity. Unmet Need: Neurodegenerative diseases are characterized by extensive deterioration of neurons or glia. Because these cells are not easily regenerated, there is an emerging unmet medical need for a therapeutic...

Published: 7/4/2024 | Inventor(s): Norman Haughey, Avindra Nath, Joseph Steiner

Keywords(s): CNS and Neurological Disorders, Disease Indication, Multiple CNS Indications, Natural compounds, Neurodegeneration, Neurodegenerative Diseases, Non-novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Neurology > Neurodegeneration, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities

Diagnostic and Prognostic Markers and Treatment Strategies for Multiple Sclerosis

C04371: Novel Diagnostic and Prognostic Multiple Sclerosis Protein BiomarkerNovelty: A novel diagnostic and prognostic protein biomarker in Cerebral Spinal Fluid that is 100% specific for Multiple Sclerosis when compared to other neurologic disorders.Value Proposition: Current Multiple Sclerosis diagnosis is produced and confirmed strictly by clinical...

Published: 7/4/2024 | Inventor(s): Caroline Anderson, David Irani, Robert Cotter, Norman Haughey, Joseph Steiner, Avindra Nath

Keywords(s): Biomarker, Chronic Inflammatory Diseases, Clinical Diagnostics, CNS and Neurological Disorders, Diagnostic Biomarker, Disease Indication, In Vitro Diagnostics, Multiple Sclerosis, Multiple Sclerosis (MS), Neurodegeneration, Prognostic Biomarker